Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

A new £60,000-a-year Alzheimer's drug, said to be the first treatment to slow progression of the memory-robbing disease, is a rip off that results in 'tiny' benefits at the cost of deadly risks ...

New research shows that lecanemab and donanemab can slow cognitive decline ... samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical and cognitive ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

By the early 1990s, the amyloid cascade hypothesis had emerged, proposing that AD is fundamentally caused by deposition of Aβ protein ... of cognitive decline. Donanemab (Eli Lilly), an amyloid ...